FOUNDATIONONE® LIQUID CDx

FOUNDATIONONE® HEME

Foundation Medicine Mobile Phlebotomy

Convenient service and scheduling

We know on-site blood draws may not be possible for all hospitals and practices. To remove this barrier, Foundation Medicine is pleased to offer in-home blood draws with mobile phlebotomy nationally, to support broader access to our FoundationOne®Liquid CDx and FoundationOne®Heme tests.

Physicians or patients can request a remote blood draw for multiple reasons such as:

- Patient is more comfortable in the privacy of their own home
- Patient lives near one of our patient phlebotomy centers
- Patient is not feeling well enough to travel
- Patient lives far from the hospital
- No on-site phlebotomy at your practice

Steps for Mobile Phlebotomy:

Day 1

Select "Mobile Phlebotomy Requested" on the completed test requisition form, Portal or EMR.

Days 2-4

Your patient will be contacted by our Client Services team to schedule an appointment with one of our vendors.

Days 4-7

A licensed phlebotomist will perform the blood draw and overnight the sample to Foundation Medicine's lab.

Days 7-21

After we receive the sample, the median turnaround time for patient results is:

FoundationOne Liquid CDx: 7 days†
FoundationOne Heme: 13 days‡

Days 2-4 and 4-7 are the rate-limiting steps, as there are variables at play:
**Patient response time and rescheduling due to phlebotomist availability can impact both.*

Foundation Medicine offers remote blood draws in every zip code of the United States, including Alaska, Hawaii and Puerto Rico, with nationwide coverage with licensed phlebotomists. Our Client Services team can assist in scheduling phlebotomy options for your patient.

To order a test, go to *www.foundationmedicine.com/order*

† Data on File, Foundation Medicine, Inc., 2023. From specimen receipt to report.
‡ Data on File, Foundation Medicine, Inc., 2023. From specimen receipt to report.

FoundationOne®Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Heme, please see its Technical Specifications at foundationmedicine.com/heme.

FoundationOne®Liquid CDx is for prescription use only and is a qualitative next-generation sequencing based in vitro diagnostic test for advanced cancer patients with solid tumors. The test analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes and as a companion diagnostic to identify patients who may benefit from treatment with specific therapies (listed in Table 1 of the Intended Use) in accordance with the approved therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Patients being considered for eligibility for therapy based on detection of NTRK1/2/3 and ROS1 fusions should only be tested if tissue is unavailable. Patients who are negative for other companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible. For the complete label, including companion diagnostic indications and complete risk information, please visit www.F1LCDxLabel.com.

FOUNDATION MEDICINE®

www.foundationmedicine.com | Tel 888.988.3639 | Fax 617.418.2290 | US-FH-2000001 V3.0